New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the seventh world conference on lung cancer

Lung Cancer

Volumn 12, Issue , 1995, Pages S63-S99

  Comis, Robert L ^a   Friedland, David M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

10 EdAM, edatrexate; 13 cis retinoic acid; 2',2' difluoro 2' deoxycytidine, gemcitabine; 4' epidoxorubicin, epirubicin; Advanced non small cell lung cancer; all trans retinoic acid; ATRA; carboplatin; CBDCA; Chemotherapy agents; cisplatin; CPT 11; CRA; cytosine arabinoside; DDP; docetaxel, taxotere; DOX; doxorubicin; DTXL; EPI; etoposide; G CSF; GEM; granulocyte colony stimulating factor; IFN; ifosfamide; IFX; IL; interferon; interleukin; irinotecan; Karnofsky Performance Scale; KPS; methotrexate; mitomycin C; MMC; MTX; NL; not listed; not statistically significant; NS; NVB; OKT3; orthoclone OKT3, murine anti CD3 monoclonal antibody; paclitaxel, taxol; Specific Chemotherapeutic Agents: Ara C; TAX; TNF; topotecan; TPT; tumor necrosis factor; VBL; VDS; vinblastine; vindesine; VP 16

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYTOKINE; DOCETAXEL; EDATREXATE; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERFERON; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OKT 3; PACLITAXEL; RETINOID DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN; TUMOR NECROSIS FACTOR; VINBLASTINE; VINDESINE;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG DESIGN; GROWTH SUBSTANCES; HUMAN; INTERFERONS; INTERLEUKINS; LUNG NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0029003818     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(10)80007-8     Document Type: Article

References (163)

1. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter randomized trial
2. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough?
3. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis
4. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer
5. Preoperative chemotherapy for stage Ilia (N2) lung cancer: The Sloan-Kettering experience with 136 patients
6. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer
7. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung cancer
8. For the Lung Cancer Study Group. The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer
9. New chemotherapeutic agents
10. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer
11. Multi-institutional phase II study of navelbine (vinorelbine) in non-small cell lung cancer
12. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients
13. Oral navelbine (NVB) for advanced stage IV non-small cell lung cancer (NSCLC)
14. A phase II study of low dose vinorelbine in patients with advanced non-small-cell lung cancer (NSCLC)
15. Results of a phase II study with vinorelbine (VNB) in patients with advanced non-small cell lung cancer (NSCLC)
16. Second line with vinorelbine in the weekly monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC)
17. Spanish Lung Cancer Group vinorelbine phase II trial in non-small cell lung cancer (NSCLC): lack of demonstrable activity with a biweekly schedule
18. Schedule modification of vinorelbine in the combination with cisplatin as a consequence of severe toxicity in advanced non-small cell lung cancer
19. Carboplatin (C) and vinorelbine (V) in metastatic (M) non-small cell lung cancer (NSCLC). Preliminary results
20. A phase I study of navelbine (NVB)-carboplatin (CBDCA) combination in non-small cell lung cancer (NSCLC)
21. A phase I/II trial of carboplatin and navelbine in advanced non-small cell lung cancer (NSCLC)
22. Carboplatin dosage: prospective evaluation of a simple formula based on renal function
23. A phase I-II trial of cisplatin (CDDP), 5-fluorouracil (5-FU), leucovorin (PFL) and navelbine (NVB) in advanced non-small cell lung cancer (NSCLC)
24. Phase II study of cisplatin (CDDP), ifosfamide (IFX) and vinorelbine (VNR) in stage IIIB-IV NSCLC
25. Ifosfamide (IFX) and navelbine (NVB) for unresectable non-small cell lung cancer (NSCLC)
26. Ifosfamide (IFO) + vinorelbine (VRL) as treatment for advanced non operable non-small cell lung cancer (NSCLC)
27. Ifosfamide (I) in combination with navelbine (N) or taxo (T) and granulocyte colony stimulating factor (G-CSF) support in advanced non-small cell lung cancer (NSCLC): 2 parallel phase I-II trials
28. Cisplatin, ifosfamide with increasing dosages of vinorelbine (NIP) in advanced non-small cell lung cancer (NSCLC)
29. Methotrexate (MTX), mitomycin c (MMC), vinorelbine (N) and cisplatinum (P) [M-MNP] in the treatment of advanced non-small cell lung cancer (NSCLC)
30. Vinorelbine (navelbine) in combination with cisplatin or mitomycin: enhancing safety, efficacy and dose-intensity
31. Randomized phase II study of vinorelbine (VNR) vs vindesine (VDS) in previously untreated non-small cell lung cancer (NSCLC)
32. Multicenter randomized trial comparing cisplatin-mitomycin-vindesine vs cisplatin-mitomycin-navelbine in advanced non-small cell lung cancer (NSCLC)
33. Taxol: an antimitotic agent with a new mechanism of action
34. Taxol stabilizes microtubules in mouse fibroblast cells
35. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results
36. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer
37. Phase II study with paclitaxel in advanced inoperable non-small cell lung cancer (NSCLC) - the European experience
38. Preliminary evaluation of a multicenter, randomized comparative study of taxol (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group
39. Phase I trial of 3-hour infusion paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
40. Taxol administered by one hour infusion: preliminary results of a phase I/II study comparing two dose schedules
41. Paclitaxel and cisplatin in advanced non-small cell lung cancer
42. Treatment of locally advanced non-small cell lung cancer (NSCLC) with taxol (1 hour infusion), cisplatin, etoposide, and radiation therapy (RT): a phase II trial
43. Phase 1 trials of taxol-containing chemotherapy regimens for the treatment of advanced non-small cell (NSCLC) and small cell lung cancer (SCLC)
44. Taxol and carboplatin in combination in stage IV and IIIB non-small-cell lung cancer (NSCLC): A phase II trial
45. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
46. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer
47. Combination trials of edatrexate with paclitaxel or cisplatin in patients with advanced non-small cell lung cancer
48. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer
49. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
50. 2 with prednisone in patients with stage IIIB and IV non-small cell lung cancer
51. A phase I trial of the combination taxotere (docetaxel) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC)
52. Single agent taxol (TAX) as second-line chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC)
53. Phase II study of taxol (T) in patients (PT) with non-small cell lung cancer (NSCLC) who have failed platinum (P) containing chemotherapy (CTX)
54. Taxotere (docetaxel: DTXL), an active agent for non-small cell lung cancer (NSCLC): preliminary report of 2 phase II studies
55. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial
56. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer
57. Extended oral etoposide (E) and oral cyclophosphamide (C) for lung cancer
58. Clinical and pharmacological phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer (NSCLC)
59. A phase II trial with oral etoposide (VP-16) and weekly cisplatin (CDDP) in non-small cell lung cancer (NSCLC)
60. Pilot phase II and toxicity trial of ifosfamide (IFF)/Mesna (M), protracted oral etoposide (VP) and cisplatinum (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
61. Chemotherapy in the treatment of non-small cell lung cancer
62. 4'-Epidoxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data
63. Toxic and therapeutic activity of 4'-Epidoxorubicin
64. Phase II trial of epirubicin in advanced squamous, adenocarcinoma and large-cell carcinoma of the lung
65. Phase II trial of 4'-epidoxorubicin in patients with non-small cell lung cancer
66. Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer
67. Phase II study of high-dose epirubicin in non-small cell lung cancer
68. A phase II study of high dose epirubicin in unresectable non-small cell lung cancer
69. Activity of high-dose epirubicin in advanced non-small-cell lung cancer
70. Phase I-II study of high-dose epirubicin advanced non-small-cell lung cancer
71. A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small cell lung cancer (NSCLC)
72. Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer
73. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer
74. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer
75. High dose epirubicin (120 mg) plus vindesine is not an effective salvage regimen for advanced non-small cell lung cancer priorly treated by a cisplatinum containing regimen
76. Final report of ifosfamide (I), cisplatinum (C) and 4-epirubicin (E) in the treatment of advanced non-small cell lung cancer (NSCLC)
77. Enhancement of C.E.V combination (cisplatin, epirubicin, vindesine) in advanced NSCLC by lonidamine. A phase II randomized trial
78. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
79. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
80. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer
81. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer
82. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
83. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer
84. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
85. A phase I trial of combination chemotherapy with irinotecan (CPT-11), cisplatin and vindesine in advanced non-small cell lung cancer (NSCLC)
86. Limited sampling models of CPT-11 and SN-38
87. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor
88. Phase I and pharmakokinetics study of topotecan, a new topoisomerase I inhibitor
89. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
90. Phase II study of topotecan in metastatic non-small-cell lung cancer
91. Phase II studies of topotecan in patients with non-small cell lung cancer (NSCLC) previously untreated and patients with small cell lung (SCLC) cancer refractory to etoposide
92. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma
93. Multicenter randomized trials in 673 comparing the combination of edatrexate, mitomycin, and vinblastine (EMV) with mitomycin and vinblastine (MV) in patients with stage III and IB non-small cell lung cancer
94. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer
95. Phase II study of 10-ethyl-10-deaza-aminopterin (10 EdAM; CGP 30 694) for stage IIIb or IB non-small-cell lung cancer
96. Phase II study of edatrexate in stage II and IV non-small-cell lung cancer
97. Incorporating 10-ethyl-10-deaza-aminopterin (EdAM) into combination therapy with mitomycin (M) and vinblastine (V) for patients (pts) with inoperable non-small-cell lung cancer (NSCLC)
98. Phase II study of 10-EdAM (10-ethyl-10-deaza-aminopterin) in non-small cell lung cancer (NSCLC)
99. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxy-cytidine and l-β-d-arabinofuranosylcytosine
100. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)
101. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
102. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study
103. Phase II study of gemcitabine in non-small-cell lung cancer (NSCLC)
104. Phase I/II study of gemcitabine (G) by 30 minute weekly intravenous (IV) infusion x 3 weeks every 4 weeks for non-small cell lung cancer
105. An extended phase II study of gemcitabine in non small cell lung cancer (NSCLC)
106. Symptomatic benefit in patients with advanced non small lung cancer (NSCLC): experience with gemcitabine
107. Results of phase II studies of gemcitabine in patients with non-small cell lung cancer (NSCLC) in Japan
108. A multicenter phase II trial with gemcitabine in non-small cell lung cancer (NSCLC)
109. Cisplatin + gemcitabine in non-small cell lung cancer (NSCLC). A phase I dose escalation study
110. Phase I study of gemcitabine (GEM) and cisplatin (CP) for advanced non-small cell lung cancer (NSCLC)
111. Phase II study of gemcitabine + vindesine in patients with prevously untreated, inoperable non-small cell lung cancer (NSCLC)
112. Diet and lung cancer. A review of the epidemiologic evidence in humans
113. Dietary vitamin A and risk of cancer in the Western Electric study
114. Vitamin A and lung cancer
115. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
116. Abnormalities in retinoic acid receptor beta (RAR beta) are common in human lung cancer
117. High frequency of retinoic acid receptor abnormalities in human lung cancer [published erratum appears in Oncogene 1992; 7: 821]
118. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
119. Adjuvant treatment of stage I lung cancer with high-does vitamin A
120. Die perorale anwendung von Vitamin A-saure bei leukoplakien, hyperkeratosen und plattenepithelikarzinomen
121. Konservative hehandlung der rezidivierenden harnblasenpapillomatose mit Vitamin A-saure
122. Response of neuroblastoma bone marrow metastases to 13 cis-retinoic acid
123. 13-cis-retinoic acid and interferon alpha-2a: effective com-bination therapy for advanced squamous cell carcinoma of the skin
124. 13-cis-retinoic acid plus interferon-alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix
125. Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer
126. Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer
127. A phase II study of all-trans retinoic acid and interferon-alpha (INF-α) in patients with advanced non-small cell lung cancer (NSCLC)
128. Phase II trial of 13-cis-retinoic acid plus interferon α in non-small-cell lung cancer
129. 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer
130. Phase II study of combination interferon beta and gamma in patients with non-small cell lung cancer (NSCLC)
131. Phase I trial of interferon-alpha-2B (IFN) and weekly cis-platin in locally recurrent or metastatic non-small cell lung cancer (NSCLC)
132. Carboplatin (CBDCA) plus α-interferon (IFNa-2a) in metastatic non-small cell lung cancer (NSCLC): a Hoosier Oncology Group (HOG) phase II trial
133. Combination chemotherapy and recombinant (R) x03B1;-interferon (IFN) for metastatic non-small cell lung cancer (NSCLC): a randomized FONICAP trial
134. Augmentation of cytotoxicity of chemotherapy by cytokines in non-small cell lung cancer
135. Phase II study with thymosin al (TA1), interferon α2a (IFN), cisplatin (DDP) and etoposide (VP16) in the treatment of advanced non-small cell lung cancer (NSCLC)
136. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
137. Interleukin 2 (IL-2) therapies prolong survival in metastatic non-small cell lung cancer (NSCLC)
138. Advanced non-small cell lung cancer (ANSCLC): Phase II study with rIL2 and aIFN in patients (pts) responsive or stable to induction chemotherapy
139. Combination immunotherapy for non-small-cell lung cancer: results with interleukin-2 and tumor necrosis factor-a
140. Immunotherapy of lung cancer
141. Recombinant human interleukin 4 (IL-4) SCH 39400 in non-small cell lung cancer (NSCLC): results of a phase II investigation
142. Phase I trial of weekly outpatient paclitaxel with concurrent thoracic radiation in non-small cell lung cancer
143. A phase I/II trial of neoadjuvant chemotherapy (CT) with cisplatin and vinorelbine (navelbine) followed by accelerated thoracic irradiation (TRT) in inoperable non-small cell lung cancer (NSCLC). Early toxicities and responses
144. Cisplatin-vinorelbine (DDP + VBN) association chemotherapy in the treatment of locally advanced NSCLC
145. Neoadjuvant chemotherapy for non-small cell lung carcinoma — stage A-B
146. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer
147. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking
148. Clinical significance of ras oncogene activation in human lung cancer
149. Novel alteration in the epidermal growth factor receptor gene is frequently detected in human non-small cell lung cancer
150. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions
151. Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics
152. Loss of heterozygosity on chromosomes 3, 13, and 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung
153. Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course
154. Increased expression of the c-myc gene without gene amplification in human lung cancer and colon cancer cell lines
155. Heterogeneity of autocrine growth stimulation mechanisms by transforming growth factor-a in human non-small cell lung cancer
156. Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer
157. Expression of gastrin-releasing peptide gene in human small-cell lung cancer
158. Selective stimulation of small-cell lung cancer clonal growth by bombesin and gastrin-releasing peptide
159. Detection of bombesin-like peptide receptors in human lung cancer cell lines with polymerase chain reaction screening
160. Response of non-small cell lung carcinomas to bombesin-like peptides
161. Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors
162. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights
163. Antitumor activity of an anti-gastrin releasing peptide (GRP) murine monoclonal antibody (2A11). Phase II trial and in vitro correlation with peptide and receptor expression